New drugs that target the endocannabinoid system are being proposed for disorders that are usually characterized by the dysregulation of social processing, like social anxiety disorder and autism spectrum disorder. Researchers have been trying to understand the mechanisms for how these drugs work.
Leah Mayo is assistant professor at the University of Calgary, and she’s one of the authors of a new study in the journal Neuropsychopharmacology in which they examined two aspects of the system. One is the endocannabinoid system itself. And then there’s another aspect of social processing called the C tactile system.
Podden och tillhörande omslagsbild på den här sidan tillhör
Springer Nature. Innehållet i podden är skapat av Springer Nature och inte av,
eller tillsammans med, Poddtoppen.
